Brainstem Dysfunction in COVID-19 Critically Ill Patients: a Prospective Observational Study
BRAINSTEM-COV
Brainstem Dysfunction in Ventilated and Deeply Sedated COVID-19 Critically Ill Patients: a Prospective Observational Study
2 other identifiers
interventional
52
1 country
2
Brief Summary
The purpose of this study is to determine the prevalence of brainstem dysfunction in critically ill ventilated and deeply sedated patients hospitalized in the Intensive Care Unit (ICU) for a SARS-CoV-s2 infection.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable covid19
Started Sep 2020
Shorter than P25 for not_applicable covid19
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 2, 2020
CompletedFirst Posted
Study publicly available on registry
August 26, 2020
CompletedStudy Start
First participant enrolled
September 14, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2020
CompletedMarch 4, 2026
March 1, 2026
4 months
June 2, 2020
March 2, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Brainstem dysfunction prevalence
Clinical cranial nerves anomalies using validated scale (BRASS score- ranges from 0 to 7 - ) in deeply sedated patient (RASS \<-3)
At inclusion or in patients with neuromuscular blockade 12h-72h following neuromuscular blocking agent cessation
Secondary Outcomes (17)
Brainstem dysfunction prevalence after sedation weaning
Day 4 to day 7 after sedation weaning
Link between brainstem dysfunction and clinical dysautonomia
At inclusion or in patients with neuromuscular blockade 12h-72h following neuromuscular blocking agent cessationn
Link between brainstem dysfunction and clinical dysautonomia after sedation weaning
4 to 7 days after sedation weaning
Characterization of brainstem dysfunction in COVID-19 patients: EEG power
At inclusion or in patients with neuromuscular blockade 12h-72h following neuromuscular blocking agent cessation
Characterization of brainstem dysfunction in COVID-19 patients: EEG power after sedation weaning
Day 4 to day 7 after sedation weaning.
- +12 more secondary outcomes
Study Arms (1)
group 1
EXPERIMENTALMajor patients, admitted in intensive care for a SARS-CoV-2 infection and requiring mechanical ventilation and deep sedation (with or without neuromuscular blockade)
Interventions
It consists of a standardized evaluation of brainstem reflexes with a score of 1 attributed for absence of pupillary light reflex, cough reflex and the combined absence of grimace and oculocephalic reflex, a score of 2 for absent corneal reflex and a score of 3 for absent grimace in the presence of oculocephalic The resulting sum ranges from 0 to 7. It will be performed at two times points: a first time under sedation and a second time 3 to 5 days after sedation weaning.
A 20 minutes clinical (12 electrodes) EEG with an EKG lead will be performed a first time under sedation and a second time 3 to 5 days after sedation weaning. These EEG recordings will allow to measure the sympathic-parasympathetic ratio using spectral analysis of the EKG and also to measure quantitative markers of brain EEG activity (spectral power and connectivity in delta, theta, alpha, beta and gamma band; complexity).
Eligibility Criteria
You may qualify if:
- ICU hospitalization
- Invasive mechanical ventilation
- Deep sedation (RASS\<-3) \>12 hours
- Positive SARS-COV-2 PCR
You may not qualify if:
- History of neurologic disease (stroke, degenerative disease)
- Pregnant women
- Moribund patients
- Minor patient
- Major patient under guardianship or curatorship
- Patient not affiliated to a social security scheme
- Limitations and cessation of active therapies
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Hôpital Cochin
Paris, 75014, France
HEGP
Paris, 75015, France
Related Publications (2)
Rohaut B, Porcher R, Hissem T, Heming N, Chillet P, Djedaini K, Moneger G, Kandelman S, Allary J, Cariou A, Sonneville R, Polito A, Antona M, Azabou E, Annane D, Siami S, Chretien F, Mantz J, Sharshar T; Groupe d'Exploration Neurologique en Reanimation (GENER). Brainstem response patterns in deeply-sedated critically-ill patients predict 28-day mortality. PLoS One. 2017 Apr 25;12(4):e0176012. doi: 10.1371/journal.pone.0176012. eCollection 2017.
PMID: 28441453BACKGROUNDBenghanem S, Cariou A, Diehl JL, Marchi A, Charpentier J, Augy JL, Hauw-Berlemont C, Gavaret M, Pene F, Mira JP, Sharshar T, Hermann B. Early Clinical and Electrophysiological Brain Dysfunction Is Associated With ICU Outcomes in COVID-19 Critically Ill Patients With Acute Respiratory Distress Syndrome: A Prospective Bicentric Observational Study. Crit Care Med. 2022 Jul 1;50(7):1103-1115. doi: 10.1097/CCM.0000000000005491. Epub 2022 Feb 9.
PMID: 35135966RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bertrand HERMANN, MD, PhD
Assistance Publique - Hôpitaux de Paris
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 2, 2020
First Posted
August 26, 2020
Study Start
September 14, 2020
Primary Completion
December 31, 2020
Study Completion
December 31, 2020
Last Updated
March 4, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share